Editas Medicine Inc. Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (27)

Latest Posts

About This Stock More About This Stock
Winners Of Q1 Earnings: 5 Best ETF Charts
Article By: Sweta Killa
Sunday, May 27, 2018 4:01 PM EST
several equity ETFs have impressed with their performances and generated handsome returns over the trailing one month even after being hit by the trade worries and geopolitical tensions. Here are five ETFs that buoyed up on robust earnings results.
In this article: PTH, SPY, PSCE, GAMR, ARKK, ILMN, SSYS, TSLA, EDIT, NTLA, MKSI, FTXL
Read
Three ‘Strong Buy’ Biotechs To Tap Now
Article By: TipRanks
Wednesday, May 16, 2018 9:58 AM EST
Which biotechs are paving the way to precisely repair the genes in the DNA?
In this article: VRTX, EDIT, CRSP
Read
E Ford Model T And Personalized Medicine
Article By: Ketan Desai
Monday, December 11, 2017 10:35 AM EST
While technology marches on, the economics of personalized medicines just don’t add up. Will they be like costly trinkets being displayed in a museum that we can watch at a distance but not own?
In this article: JUNO, KITE, EDIT
Read
Editas Medicine, Inc., Announces Pricing Of $50 Million Offering Of Common Stock
Article By: NASDAQ GlobeNewswire
Wednesday, December 6, 2017 12:25 PM EST
Editas Medicine, Inc., a leading genome editing company, today announced the pricing of an underwritten offering of 1,970,000 shares of its common stock.
In this article: EDIT
Read
HH Small Cap Biotech Stocks Soar: How Long Will Rotation Last?
Article By: Rod Raynovich
Thursday, October 5, 2017 9:06 PM EST
Speculation in small cap biotech picks up, a boon for diligent traders. ETF buying is driving all small cap and microcap stocks higher.
In this article: AVEO, ZIOP, IJS, IWC, IWM, XBI, FPRX, RXDX, XNCR, CNCR, EDIT
Read

PARTNER HEADLINES

Latest Tweets for $EDIT

No tweets yet!

$EDIT

Editas Medicine, Inc., Announces Pricing Of $50 Million Offering Of Common Stock
Michael Molman 12/6/2017 5:41:11 PM

Looking forward to hearing more information about $EDIT. Company seems to operate in a very exiting and potentially fast growing new field.

1 to 1 of 1 comments